Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Lemborexant by Eisai for Reflux Esophagitis (Gastroesophageal Reflux Disease): Likelihood of Approval
Lemborexant is under clinical development by Eisai and currently in Phase II for Reflux Esophagitis (Gastroesophageal Reflux Disease). According to...